Pathways to Access Summit (Paths)
Psychedelic Therapeutics in Europe and Beyond
5 June, 2024 | Philharmonie, Haarlem | The Netherlands
Add-on event the day before ICPR 2024
Add-on event the day before ICPR 2024
Pathways to Access Summit (Paths)
Psychedelic Therapeutics in Europe and Beyond
5 June, 2024 | Philharmonie, Haarlem | The Netherlands
Add-on event the day before ICPR 2024
Add-on event the day before ICPR 2024
Pathways to Access Summit (Paths)
Psychedelic Therapeutics in Europe and Beyond
5 June, 2024 | Philharmonie, Haarlem | The Netherlands
Add-on event the day before ICPR 2024
Add-on event the day before ICPR 2024
A Full Day of Insightful Exploration
A Full Day of Insightful Exploration
A Full Day of Insightful Exploration
Watch the video of OPEN Foundation's director explaining the Pathways to Access Summit (Watch till the end!)
Watch the video of OPEN Foundation's director explaining the Pathways to Access Summit
(Watch till the end!)
With the FDA likely approving MDMA-assisted therapy as a treatment for PTSD later this year in the United States, and the evidence supporting the potential of psychedelic therapies further accumulating, 2024 is shaping up to be a pivotal year for the therapeutic use of psychedelics. However, the path to approval and - crucially - patient access in Europe remains uncertain.
The full-day Pathways to Access Summit (Paths) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.
This summit will unravel the complexities of European regulatory frameworks, addressing the diverse and ever-changing healthcare systems, assessments for pricing and reimbursement, and unique regulatory challenges. We will identify which stakeholders to engage with at each stage of the journey from bench to bedside and share best practices for doing so. We will discuss how to effectively navigate the European regulatory landscape, incorporating insights from other regulatory systems, and offer a well-rounded perspective on the different approaches and best practices to psychedelic medicine regulation.
With growing interest in the potential of psychedelic therapies for mental disorders, understanding the regulatory frameworks and pathways to access of these treatments is now more pertinent than ever.
At the full-day Pathways to Access Summit (PATHS), we will explore what the integration of psychedelic medicines into mainstream European mental health services will entail. During this interactive event, we will delve into the evolving pathways for accessing these innovative treatments, and focusing on safe, timely, and ethical implementation. We will unravel the complexities of European regulatory frameworks, addressing all different stages: from clinical research to reimbursable treatments, which stakeholders to involve in what phase, and how to navigate this process efficiently.
PATHS is a stand-alone event leading up to ICPR, which builds on the insights of the 2022 Psychedelic Science, Ethics & Business Symposium.
Key Questions to be Addressed
Key Questions to be Addressed
Key Questions to be Addressed
With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:
With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:
With participation from key stakeholders, EU institutions and global experts, this summit will focus on the following questions:
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
What are the prevalent compliance and availability challenges several nations are presently wrestling with?
What can we learn from different countries and regulatory regimes that might be replicated—or avoided—in the EU?
Similarly, what can we learn from the challenges faced and strategies employed by stakeholders to roll out other first-in-class therapies?
What steps can regulators, drug developers, researchers, and policymakers take today to advance equitable access to psychedelic-assisted treatments?
Paths Programme
Paths Programme
Paths Programme
Open Space Sessions
Open Space Sessions
Open Space Sessions
Co-Creating the Future of Psychedelic Medicines
Co-Creating the Future of Psychedelic Medicines
Co-Creating the Future of Psychedelic Medicines
Designed to leverage the innovative concept of Unconferencing, OPEN Space Sessions will allow you, the attendees, to actively participate and shape our agenda, If you have a session idea, you will have a chance to host a session and share your knowledge.
Why are we doing this?
We believe in the collective expertise of our attendees. This interactive approach ensures that Paths not only addresses the predefined topics, but also the pressing issues brought forth by you, the participants.
Why are we doing this?
We believe in the collective expertise of our attendees. This interactive approach ensures that Paths not only addresses the predefined topics, but also the pressing issues brought forth by you, the participants.
Why are we doing this?
We believe in the collective expertise of our attendees. This interactive approach ensures that Paths not only addresses the predefined topics, but also the pressing issues brought forth by you, the participants.
How does it work?
If you are interested in hosting a session, you can do so in 2 ways:
On the Day Pitching
At the start of the segment, we will host a pitching session where you can present your session idea, and fellow participants can vote on it.
Online Submission
Prior to the event, you can submit your session idea on our community platform. You and other participants can vote on the ideas.
How does it work?
If you are interested in hosting a session, you can do so in 2 ways:
On the Day Pitching
At the start of the segment, we will host a pitching session where you can present your session idea, and fellow participants can vote on it.
Online Submission
Prior to the event, you can submit your session idea on our community platform. You and other participants can vote on the ideas.
How does it work?
If you are interested in hosting a session, you can do so in 2 ways:
On the Day Pitching
At the start of the segment, we will host a pitching session where you can present your session idea, and fellow participants can vote on it.
Online Submission
Prior to the event, you can submit your session idea on our community platform. You and other participants can vote on the ideas.
Who is it hosted by?
This part of Paths will be led by Marcus Druen.
He has facilitated highly interactive and invigorating collaboration and authentic relating events for up to 1,500 participants.
Who is it hosted by?
This part of Paths will be led by Marcus Druen.
He has facilitated highly interactive and invigorating collaboration and authentic relating events for up to 1,500 participants.
Who is it hosted by?
This part of Paths will be led by Marcus Druen.
He has facilitated highly interactive and invigorating collaboration and authentic relating events for up to 1,500 participants.
Are you ready to co-create the future of psychedelic medicines together?
Are you ready to co-create the future of psychedelic medicines together?
Are you ready to co-create the future of psychedelic medicines together?
Speakers
Speakers
Speakers
Get the latest updates on speakers, programme and more, including discount tickets by subscribing below to the ICPR Newsletter.
Who is Paths for?
Who is Paths for?
Who is Paths for?
This one-day summit is essential for those invested in the future of psychedelic medicines.
This one-day summit is essential for those invested in the future of psychedelic medicines.
This one-day summit is essential for those invested in the future of psychedelic medicines.
Academia
Academia
Academia
* Clinical scientists / CRO's
* Researchers
* Students
* Clinical scientists / CRO's
* Researchers
* Students
* Clinical scientists / CRO's
* Researchers
* Students
Politics & Society
Politics & Society
Politics & Society
* Policymakers / Regulators
* Healthcare professionals
* Psychedelic industry professionals
* Patients
* Policymakers / Regulators
* Healthcare professionals
* Psychedelic industry professionals
* Patients
* Policymakers / Regulators
* Healthcare professionals
* Psychedelic industry professionals
* Patients
Business
Business
Business
* Investors
* Insurers
* Executives
* Investors
* Insurers
* Executives
* Investors
* Insurers
* Executives
Practicalities
Practicalities
Practicalities
Date
Date
Date
5th of June, 2024
09:00 - 18:00 CET
The day before ICPR 2024
5th of June, 2024
09:00 - 18:00 CET
The day before ICPR 2024
5th of June, 2024
09:00 - 18:00 CET
The day before ICPR 2024
Location
Location
Location
Philharmonie, Haarlem
The Netherlands
Same location as ICPR 2024
Philharmonie, Haarlem
The Netherlands
Same location as ICPR 2024
Philharmonie, Haarlem
The Netherlands
Same location as ICPR 2024
Ticketing Options
Ticketing Options
Tickets
Paths Regular Ticket
€299
In-Person Ticket for Attendees
Includes on-site access to the Pathways to Access Summit on Wednesday.
Full Venue and Programme Access PLUS:
Meet and Network with 300+ Attendees
Badging: Name, Title, Org
Regular OPEN Membership
Access All Recorded Content
Food, Beverages
Coffee, tea, fruits, snacks, water, plus a healthy vegetarian, mainly organic lunch!
ICPR + Paths Package Deals
ICPR + Paths Package Deals
Do you know about the 2024 Expert-Led Workshops?
Do you know about the 2024 Expert-Led Workshops?
Do you know about the 2024 Expert-Led Workshops?
Learn directly from world-esteemed experts in psychedelic therapy by joining one of two exclusive full-day workshops with at the cutting edge.
An enriching experience that will expand your knowledge and connect you with a community of forward-thinking professionals.
Paths and the workshops are held at the same time, requiring attendees to select either a workshop or the Paths event.
Learn directly from world-esteemed experts in psychedelic therapy by joining one of two exclusive full-day workshops with at the cutting edge.
An enriching experience that will expand your knowledge and connect you with a community of forward-thinking professionals.
Paths and the workshops are held at the same time, requiring attendees to select either a workshop or the Paths event.
Learn directly from world-esteemed experts in psychedelic therapy by joining one of two exclusive full-day workshops with at the cutting edge.
An enriching experience that will expand your knowledge and connect you with a community of forward-thinking professionals.
Paths and the workshops are held at the same time, requiring attendees to select either a workshop or the Paths event.
